NCT02667080已完成不适用
Parameters of Sperm Quality in Consecutive Sperm Samples From Males Partners of Couples Seeking Treatment for Infertility
Aalborg University2 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2014年4月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 试验地点
- 2
- 主要终点
- Routine semen quality assessment
研究概览
简要总结
The main purpose of the study is to assess to which degree a series of sperm parameters known to be associated with fertilization and implantation potential in artificial reproductive technology (ART) differ in consecutive sperm samples produced after 2-7 days and 2 hours of sexual abstinence in males from couples referring for ART treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •male age between 18 and 50
- •able to understand and read Danish
排除标准
- •complete azospermia
- •significant psychological illness
- •significant cardiovascular disease
结局指标
主要结局
Routine semen quality assessment
时间窗: After liquefaction (30-35 minutes after ejaculation)
Routine sperm quality check including Morphology, Motility and DNA fragmentation index using both the conventional manual method and computer assisted sperm analysis (CASA) systems.
次要结局
- Outcome of ART treatments(up to one year after the sampling)
研究者
Hiva Alipour
Ph.D. Student, Research Assistant
Aalborg University
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
不适用
SpermQT Prospective Observational TrialMale InfertilityNCT05966883Inherent Biosciences1,000
终止
不适用
Impact of Sperm DNA Integrity on Artificial Reproductive Treatment (ART)Sperm DNA Impact on ART OutcomesNCT00875095Northwell Health8
终止
不适用
Study of the Spermatic Characteristics of Patients With Fabry DiseaseFabry DiseaseNCT04073888University Hospital, Bordeaux22
尚未招募
3 期
Sperm selection by cumulus columIRCT20180130038561N2Yazd University of Medical Sciences100
撤回
不适用
A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0Male InfertilityNCT02839447Aytu BioPharma, Inc.